article thumbnail

New Research Reveals How Air Pollution May Trigger Lung Cancer

XTalks

Having a mutation in one copy of either the EGFR and/or KRAS gene isn’t enough to lead to lung cancer. Most cancers follow the double-hit model where a mutation in the second copy of the gene is required for the cancer to form. The Double Hit. The new research shows that air pollutants can be that ‘second hit.’

article thumbnail

How biomarkers can help discover new treatments for women’s health

Drug Discovery World

We previously conducted a hypothesis-free study using genotype data from the UK Biobank, which resulted in the first mechanism-based stratification of endometriosis patients. SG: Chronic diseases, like endometriosis, are polygenic, caused by a complex interplay of multiple genes and other factors.

Genome 72
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

XTalks

From a total of 30 single-nucleotide polymorphisms (SNPs) in genes previously identified as being associated with blood pressure, many had a relatively neutral effect on the risk of coronary artery disease. Figure 2: Using drug-target MR to validate sympathetic nervous system genes involved in heart failure.

article thumbnail

Artificial intelligence could be new blueprint for precision drug discovery

The Pharma Data

.” In the new study, Ghosh and colleagues replaced the first and last steps in preclinical drug discovery with two novel approaches developed within the UC San Diego Institute for Network Medicine (iNetMed), which unites several research disciplines to develop new solutions to advance life sciences and technology and enhance human health.

Drugs 52
article thumbnail

Reflecting on ELRIG’s Drug Discovery 2022 

Drug Discovery World

The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK.

Drugs 52
article thumbnail

Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

The Pharma Data

Another key focus at Bayer is on innovative precision oncology treatments, with an approved TRK inhibitor exclusively designed to treat tumors that have an NTRK gene fusion, the oncogenic driver of tumor growth and spread. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.